What tissues can be used in ex vivo screening?

Creative Biolabs supports a wide range of tissue types, including human biopsy samples, animal organs, tumor slices, and disease-model tissues. We also offer validated tissue panels for common indications and can assist in sourcing specialized tissues if needed.

How is ex vivo different from in vivo or in vitro screening?

Ex vivo allows you to screen on real tissues without the complexities of live animal work, preserving architecture and microenvironment while maintaining experimental control. It offers a more relevant alternative to in vitro models while avoiding the ethical and logistical challenges of in vivo studies.

Can I use my own tissue samples?

Yes, we accept client-supplied samples with guidance on preparation and shipment. Creative Biolabs will assist with quality control and documentation to ensure optimal results.

Do you offer target identification services?

Yes. For selected ligands, Creative Biolabs offers receptor pull-down, mass spectrometry, target deconvolution, and validation assays to help identify binding partners and their biological relevance.

How long does a typical campaign take?

Depending on complexity and rounds, most projects are completed within 8-12 weeks. More advanced screening campaigns or those requiring downstream validation may take longer.

Is your platform suitable for rare diseases or personalized medicine?

Absolutely. Creative Biolabs' ex vivo services are well-suited for rare disease models, patient-derived samples, and custom phenotyping strategies. We can adapt our workflow to limited material and help uncover disease-specific targets.

What kind of data analysis is included?

Our analysis includes ranking by enrichment, sequence clustering, motif detection, and biological annotation. For deeper insights, optional structural modeling or pathway analysis can be added.

Are your services compatible with clinical or diagnostic development?

While Creative Biolabs provides research-grade services, our workflows and quality standards are designed to support transition to clinical development. We also assist clients in early-stage IND or biomarker validation pipelines when required.

Ex Vivo Phage Library Screening Service

Introduction Our Services Workflow Platform Advantages Deliverables FAQ

Introduction: Precision Meets Practicality

Ex vivo phage display screening bridges the gap between in vitro simplicity and in vivo complexity. By allowing phage-displayed peptide or antibody libraries to interact with freshly isolated or preserved biological tissues and cells outside the body, researchers can access physiologically relevant targets while maintaining high experimental control. At Creative Biolabs, we specialize in highly customized ex vivo phage screening services, empowering our clients to identify high-affinity ligands, antibodies, or protease substrates that are biologically meaningful, yet experimentally tractable.

Creative Biolabs' ex vivo services are particularly suitable for studies requiring human tissue access, personalized model systems, or ethically restricted research contexts. Whether you're exploring tumor microenvironments, fibrotic organs, or patient-derived xenografts (PDX), Creative Biolabs provides end-to-end support for a seamless screening experience.

What We Offer: Tailored Screening Solutions

Creative Biolabs' ex vivo phage display services are designed to serve both discovery-driven and hypothesis-driven research. Our team works closely with clients to select the optimal tissue models, screening strategy, and validation pipeline. Key service features include:

Screening of phage peptide, scFv, Fab, or single-domain antibody libraries against fresh-frozen, paraformaldehyde-fixed, or perfused tissue sections
Tissue sources include tumor biopsies, human organs (via ethical procurement), animal disease models, and explanted cell sheets
Pre-blocking and depletion steps to reduce background binding and increase specificity
Single- or multi-round screening with intermediate enrichment analysis
Downstream target validation and ligand characterization options

Clients can supply their own tissues or choose from Creative Biolabs' ethically sourced panel of validated models. Get in touch to find out more.

How It Works: Our Stepwise Discovery Approach

Our workflow integrates rigor, flexibility, and biological relevance at each stage:

Consultation & Design

Define the tissue model, library type, and screening objective with Creative Biolabs scientists.

Sample Preparation

Tissues are freshly prepared or recovered from archives with optimal preservation protocols.

Phage Library Incubation

The library is applied under physiological conditions to allow for selective binding.

Washing & Elution

Unbound phages are removed, and tissue-bound phages are eluted under gentle conditions.

Amplification & Re-screening

Recovered phage clones are amplified and subjected to additional rounds if needed.

DNA Extraction & Sequencing

Clone inserts are sequenced via Sanger or NGS approaches.

Bioinformatic Ranking

Enriched sequences are ranked by abundance, redundancy, and motif clustering.

Optional Functional Testing

High-ranking candidates may undergo binding assays, target identification, or synthetic modification.

Fig.1 Workflow of Ex vivo Phage Display Screening. (Creative Biolabs Original) Fig.1 Procedure for ex vivo phage display selection.

Our Platform: A Bridge Between Systems Biology and Experimental Control

Creative Biolabs' ex vivo phage screening platform combines the best of both worlds—preserved physiological architecture with flexible, high-throughput screening capabilities. Unlike traditional in vitro systems that often lack spatial and structural context, our platform allows library candidates to interact with real tissue environments, maintaining extracellular matrix cues, vascular structures, and cell-cell interactions.

This approach enables:

Target discovery in rare or delicate tissues where in vivo screening is infeasible
Identification of ligands that are conformation- or state-specific (e.g., hypoxia-induced epitopes)
Multi-region screening within the same sample (e.g., tumor core vs. margin)
Comparative analysis across disease stages or patient subtypes

Our modular platform is also adaptable for other complementary library screening services offered by Creative Biolabs, such as:

In Vivo Phage Display Services	Therapeutic Antibody Discovery	Protease Substrate Screening
Solid-phase and Solution-phase Library Screening	Cell-based Library Screening	Rapid Recovery of scFv from Tissue-Selected Pools

Why Creative Biolabs? The Benefits of Working with Us

Tissue-Specific Expertise

From brain slices to liver biopsies, Creative Biolabs has experience working with complex and delicate tissues.

Flexible Sample Formats

Accepting fresh, frozen, fixed, or perfused tissues, with quality checks and preservation support.

End-to-End Integration

From tissue sourcing to peptide synthesis and functional validation.

Responsive Team

Dedicated project coordinators and regular update reports ensure transparency and success.

Connect with us to discover more.

Your Results: Deliverables You Can Act On

When you work with Creative Biolabs, you receive far more than raw data. Our standard deliverables include:

Detailed experimental report outlining methods, results, and interpretation
Sequencing results from phage clones or pools (Sanger/NGS as appropriate)
Ranked hit lists with motif analysis and biological annotation
Custom alignment and clustering reports
Optionally: Synthetic peptide/single-domain antibody production, ELISA validation, or immunostaining data
Recommendations for next-phase development or therapeutic translation

We also provide support for grant writing, publications, and patent documentation if needed. Contact Creative Biolabs today to start designing your customized ex vivo phage library screening project. Discover ligands that matter—where biology meets precision.

FAQs: Your Concerns Addressed

What tissues can be used in ex vivo screening?
A: Creative Biolabs supports a wide range of tissue types, including human biopsy samples, animal organs, tumor slices, and disease-model tissues. We also offer validated tissue panels for common indications and can assist in sourcing specialized tissues if needed.
How is ex vivo different from in vivo or in vitro screening?
A: Ex vivo allows you to screen on real tissues without the complexities of live animal work, preserving architecture and microenvironment while maintaining experimental control. It offers a more relevant alternative to in vitro models while avoiding the ethical and logistical challenges of in vivo studies.
Can I use my own tissue samples?
A: Yes, we accept client-supplied samples with guidance on preparation and shipment. Creative Biolabs will assist with quality control and documentation to ensure optimal results.
Do you offer target identification services?
A: Yes. For selected ligands, Creative Biolabs offers receptor pull-down, mass spectrometry, target deconvolution, and validation assays to help identify binding partners and their biological relevance.
How long does a typical campaign take?
A: Depending on complexity and rounds, most projects are completed within 8-12 weeks. More advanced screening campaigns or those requiring downstream validation may take longer.
Is your platform suitable for rare diseases or personalized medicine?
A: Absolutely. Creative Biolabs' ex vivo services are well-suited for rare disease models, patient-derived samples, and custom phenotyping strategies. We can adapt our workflow to limited material and help uncover disease-specific targets.
What kind of data analysis is included?
A: Our analysis includes ranking by enrichment, sequence clustering, motif detection, and biological annotation. For deeper insights, optional structural modeling or pathway analysis can be added.
Are your services compatible with clinical or diagnostic development?
A: While Creative Biolabs provides research-grade services, our workflows and quality standards are designed to support transition to clinical development. We also assist clients in early-stage IND or biomarker validation pipelines when required.